Fig. 7
Reverse transcriptase inhibitor and 12-LOX inhibitor impaired growth of LUSC xenografts and reversed immunosuppressive microenvironment in vivo. A KLN205OV−CTRL and KLN205OV−L1−FGGY were inoculated subcutaneously in the DBA2 mice which were subjected to either NVR (50 mg/kg/day) or ML355 (3 mg/kg/day) treatment, or subjected with the two inhibitors simultaneously. Representative images of the forming tumors were shown. B The tumor volume (left panel) and body weight (right panel) of the mice at various time points upon injection. C The qPCR results of genes involved in AA metabolic pathways (left) and qPCR results of genes involved in Wnt signaling (right) were shown as relative expression values in KLN205OV−CTRL mouse group, KLN205OV−L1−FGGY mouse group, NVR-treated KLN205OV−L1−FGGY mice, ML355-treated KLN205OV−L1−FGGY mice and NVR + ML355-treated KLN205OV−L1−FGGY mouse group. D Western blot results to detect expression of FGGY, 12-LOX, and GPR31 in different mouse groups we constructed. E The proportions of various immunocytes in different mouse groups using multispectral immuno-fluorescent staining. F Representative images of multispectral immuno-fluorescent staining results